The short answer
A swallowed peptide faces three sequential barriers: acid hydrolysis in the stomach, enzymatic cleavage by proteases, and poor permeability across the intestinal wall because peptides are large and polar. Oral bioavailability for an unmodified peptide is typically well under one percent, which is why almost all therapeutic peptides are injected.
Key facts
- Barrier 1
- Gastric acid (pH ~1.5-3.5)
- Barrier 2
- Pepsin, trypsin, chymotrypsin, DPP-4
- Barrier 3
- Low permeability (large, polar molecules)
- Typical oral bioavailability
- Well below 1% unmodified
- Known workaround
- Permeation enhancers such as SNAC
- Alternative
- Abandon the peptide backbone entirely
The three barriers in order
Acid comes first. The stomach sits around pH 1.5 to 3.5, and prolonged exposure hydrolyses peptide bonds without any enzyme involved. Enzymes come second: pepsin in the stomach, then trypsin and chymotrypsin in the small intestine, each cleaving at characteristic residues. Anything that survives both meets the third barrier, which is simple physical chemistry. Peptides are large and heavily hydrogen-bonded, and the intestinal epithelium does not readily let such molecules across.
Why DPP-4 matters specifically for incretins
Dipeptidyl peptidase-4 removes the first two residues from the N-terminus of native GLP-1, and that alone inactivates it. Endogenous GLP-1 has a half-life of roughly one to two minutes as a result. Every long-acting incretin analogue is, in part, an exercise in engineering around this single enzyme, usually by substituting the residue DPP-4 recognises and by adding a fatty-acid chain that binds albumin to slow renal clearance.
Research material referenced
Retatrutide 10mg, third-party HPLC tested
How absorption enhancers work
Salcaprozate sodium, usually written SNAC, is co-formulated with oral semaglutide. It raises local pH in the immediate vicinity of the tablet, which protects the peptide from acid and pepsin, and transiently increases permeability of the gastric mucosa so some fraction of the dose crosses. It is effective but conditional: it depends on the tablet sitting in a relatively empty stomach with a small, defined volume of water, which is why oral semaglutide carries fasting instructions.
The other route: stop using a peptide
The alternative to protecting a fragile molecule is designing one that was never fragile. Orforglipron has no peptide bonds, so acid and proteases have nothing to act on, and its size and polarity were optimised for permeability from the start. It needs no enhancer and carries no food or water conditions. This is why its 2026 authorisation is discussed as a formulation milestone rather than only an efficacy result.
What this means for handling research peptides
The same chemistry explains standard laboratory practice. Peptides are supplied lyophilised because water enables hydrolysis; they are reconstituted immediately before use, kept cold, and protected from repeated freeze-thaw cycles. A peptide left in solution at room temperature is subject to the same bond chemistry that defeats oral administration, only more slowly.
Frequently asked questions
Do any peptides work orally without help?
Very few, and generally only small, unusually rigid ones such as cyclosporine, whose cyclic structure resists proteases. Linear peptides of incretin size do not.
Is SNAC an active drug?
No. It is a formulation excipient. It has no GLP-1 activity of its own; it only helps the peptide survive and cross.
Why are research peptides supplied as a freeze-dried powder?
Because removing water removes the main route to hydrolysis. A lyophilised peptide stored cold and dry is far more stable than the same peptide in solution.
Continue researching
Related guides and reference material.
Primary sources & clinical trials
Published papers, trial registrations, regulator pages and company announcements. Links open the original.
Written and published by UK Peptides, the trading name of AURYXRESEARCH LTD (company 17388727, registered in England and Wales).
Questions or a correction? Email hello@ukpeptides.org or call +44 7426 987848.
More Research & Regulatory News articles
- Retatrutide TRIUMPH-1: The Phase 3 ResultsTRIUMPH-1 reported mean weight reduction of 28.3% at 80 weeks on 12 mg retatrutide, and 30.3% at 104 weeks. Full dose-arm figures and adverse events.
- Retatrutide TRIUMPH-2 and TRIUMPH-3: What They AddedTRIUMPH-2 and TRIUMPH-3 reported in July 2026, covering type 2 diabetes and cardiovascular disease. Results, context and the remaining readouts.
- Where the MHRA Draws the Line on Research PeptidesUK law regulates claims and intended use, not the compound. What makes a product an unlicensed medicine, and how the MHRA has enforced that line in 2026.
- Counterfeit GLP-1 Products: The 2026 UK PictureMHRA seizures of counterfeit GLP-1 pens, a 265% rise in US poison-centre exposures, and why certificate-of-analysis verification is the only practical defence.
- Orforglipron in the UK: Access, Cost and the NHS QuestionFoundayo is available in the UK on private prescription only, reported at roughly £99-£179 a month. NHS funding awaits NICE guidance expected 18 November 2026.